We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-18.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$161M
AUM Growth
-$49.3M
Cap. Flow
-$8.81M
Cap. Flow %
-5.46%
Top 10 Hldgs %
56.91%
Holding
57
New
6
Increased
7
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.65M
2
GILD icon
Gilead Sciences
GILD
+$8.6M
3
BIIB icon
Biogen
BIIB
+$5.49M
4
AMGN icon
Amgen
AMGN
+$4.68M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.21M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$11.7M
2
ILMN icon
Illumina
ILMN
+$5.73M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$5.67M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.17M
5
PBYI icon
Puma Biotechnology
PBYI
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTHX
51
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-72,000
Closed -$2.88M
DCPH
52
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-77,000
Closed -$2.29M
CBAY
53
DELISTED
Cymabay Therapeutics
CBAY
– –
-145,000
Closed -$1.23M
PRTK
54
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-103,500
Closed -$766K
SPPI
55
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-300,000
Closed -$3.86M
ADMS
56
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-370,000
Closed -$5.67M
RSLS
57
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
– –
-375
Closed -$2K
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2018 Portfolio in Review

As of Q4 2018, International Biotechnology Trust held 57 positions worth $161M, down 23% from $210M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust withdrew a net $8.81M in Q4 2018, closing 12 positions and reducing 18 holdings. Its most notable exit was Adamas Pharmaceuticals, an estimated $5.67M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $4.06M.

  • International Biotechnology Trust's largest Q4 2018 buy was Biogen: 17,200 shares worth $4.06M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q4 2018, an estimated $8.65M increase.
  • International Biotechnology Trust's biggest Q4 2018 reduction was Array Biopharma Inc, cutting an estimated $11.7M.
  • International Biotechnology Trust fully exited Adamas Pharmaceuticals in Q4 2018, selling an estimated $5.67M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $161M portfolio in Q4 2018.
  • International Biotechnology Trust opened 6 new positions and closed 12 in Q4 2018.
  • International Biotechnology Trust's portfolio value fell 23% quarter-over-quarter to $161M.

Based on International Biotechnology Trust's 13F filing for Q4 2018, filed 14 Feb 2019.